288383-20-0 | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$10.00	$7.00
5mg	98%	in stock	$22.00	$16.00
10mg	98%	in stock	$33.00	$23.00
100mg	98%	in stock	$134.00	$94.00
250mg	98%	in stock	$299.00	$209.00
1g	98%	in stock	$713.00	$499.00

Description

• Catalog Number: AI46583
• Chemical Name: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
• CAS Number: 288383-20-0
• Molecular Formula: C25H27FN4O3
• Molecular Weight: 450.5053
• MDL Number: MFCD09954115
• SMILES: COc1cc2c(ncnc2cc1OCCCN1CCCC1)Oc1ccc2c(c1F)cc([nH]2)C

Computed Properties

• Complexity: 625
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 8
• XLogP3: 4.9

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.

  Journal of medicinal chemistry 20121227

• Targeted therapy in brain metastasis.

  Current opinion in oncology 20121101

• Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

  Radiology 20121101

• Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.

  International journal of cancer 20121015

• Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20121010

• Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20121010

• Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.

  Investigational new drugs 20121001

• Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.

  Anti-cancer agents in medicinal chemistry 20121001

• Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.

  Critical reviews in oncology/hematology 20121001

• Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

  Lung cancer (Amsterdam, Netherlands) 20121001

• Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

  The Prostate 20120901

• Beyond bevacizumab: antiangiogenic agents.

  Clinical lung cancer 20120901

• A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

  Current cancer drug targets 20120901

• Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].

  Magyar onkologia 20120901

• Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.

  Oncotarget 20120901

• Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.

  American journal of clinical oncology 20120801

• Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

  Investigational new drugs 20120801

• Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.

  Investigational new drugs 20120801

• Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.

  Anti-cancer drugs 20120801

• Kidney injury during VEGF inhibitor therapy.

  The Netherlands journal of medicine 20120801

• Antiangiogenic approaches for the treatment of advanced synovial sarcomas.

  Current opinion in oncology 20120701

• Cediranib: a VEGF receptor tyrosine kinase inhibitor.

  Future oncology (London, England) 20120701

• Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

  Cancer metastasis reviews 20120601

• An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.

  Cancer chemotherapy and pharmacology 20120601

• Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.

  Critical reviews in oncology/hematology 20120501

• Using electron induced dissociation (EID) on an LC time-scale to characterize a mixture of analogous small organic molecules.

  Journal of the American Society for Mass Spectrometry 20120501

• Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.

  The Journal of pharmacology and experimental therapeutics 20120501

• Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

  Journal of neuro-oncology 20120501

• Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

  Expert opinion on investigational drugs 20120501

• Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501

• Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501

• Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

  Pediatric blood & cancer 20120401

• Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.

  Journal of neuro-oncology 20120401

• Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

  Acta neuropathologica 20120301

• Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120301

• Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

  European journal of cancer (Oxford, England : 1990) 20120301

• [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

  Magyar onkologia 20120301

• Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?

  Cancer biology & therapy 20120301

• Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20120201

• Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

  Cancer research 20120115

• Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.

  International journal of radiation oncology, biology, physics 20120101

• Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

  Journal of oncology 20120101

• Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.

  Journal of oncology 20120101

• Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.

  Journal of oncology 20120101

• Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma.

  Journal of oncology 20120101

• Novel therapies in phase II and III trials for malignant pleural mesothelioma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20120101

• Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).

  PloS one 20120101

• Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

  PloS one 20120101

• Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.

  Neoplasia (New York, N.Y.) 20120101

• Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.

  BMC cancer 20120101

• Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.

  Journal of oncology 20120101

• Novel therapies in glioblastoma.

  Neurology research international 20120101

• Current trends in targeted therapies for glioblastoma multiforme.

  Neurology research international 20120101

• Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.

  PloS one 20120101

• Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies.

  Sarcoma 20120101

• The molecular biology of soft-tissue sarcomas and current trends in therapy.

  Sarcoma 20120101

• Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature.

  Sarcoma 20120101

• Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

  PloS one 20120101

• Metastatic gastric cancer - focus on targeted therapies.

  Biologics : targets & therapy 20120101

• Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111215

• Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.

  Investigational new drugs 20111201

• [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

  Revue des maladies respiratoires 20111201

• Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.

  Journal of neuro-oncology 20111101

• Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• Clinical experience with antiangiogenic therapy in leukemia.

  Current cancer drug targets 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20111001

• Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.

  British journal of cancer 20110927

• A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

  Cancer chemotherapy and pharmacology 20110901

• Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.

  Journal of neuro-oncology 20110901

• Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.

  European journal of cancer (Oxford, England : 1990) 20110801

• Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

  Current neurology and neuroscience reports 20110601

• Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

  Cancer research 20110601

• Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

  Journal of the National Cancer Institute 20110504

• Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

  Molecular cancer therapeutics 20110501

• Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.

  Cancer investigation 20110501

• Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.

  Expert review of anticancer therapy 20110501

• Overview of anti-angiogenic agents in development for ovarian cancer.

  Gynecologic oncology 20110401

• Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

  Current oncology reports 20110401

• Recurrent high-grade glioma: a diagnostic and therapeutic challenge.

  Expert review of neurotherapeutics 20110401

• Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

  North American journal of medical sciences 20110401

• Sunitinib and other targeted therapies for renal cell carcinoma.

  British journal of cancer 20110301

• Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.

  British journal of cancer 20110201

• In pursuit of new anti-angiogenic therapies for cancer treatment.

  Frontiers in bioscience (Landmark edition) 20110101

• Targeting angiogenesis in childhood sarcomas.

  Sarcoma 20110101

• Glioblastoma recurrence after cediranib therapy in patients: lack of 'rebound' revascularization as mode of escape.

  Cancer research 20110101

• Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.

  Radiation oncology (London, England) 20110101

• Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

  Sarcoma 20110101

• Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.

  PloS one 20110101

• Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

  BMC cancer 20110101

• Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.

  BMC cancer 20110101

• Renal involvement in preeclampsia: similarities to VEGF ablation therapy.

  Journal of pregnancy 20110101

• Novel therapeutic strategies for targeting liver cancer stem cells.

  International journal of biological sciences 20110101

• Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.

  Cardiology research and practice 20110101

• Tumor angiogenesis and vascular patterning: a mathematical model.

  PloS one 20110101

• Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC.

  OncoTargets and therapy 20110101

• Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

  Breast cancer research : BCR 20110101

• Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

  Cancer management and research 20110101

• Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

  BMC cancer 20110101

• Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.

  PloS one 20110101

• Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

  International journal of molecular sciences 20110101

• Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.

  Clinical Medicine Insights. Oncology 20110101

• Innovative Therapies against Human Glioblastoma Multiforme.

  ISRN oncology 20110101

• New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.

  Therapeutics and clinical risk management 20110101

• New agents targeting angiogenesis in glioblastoma.

  Chemotherapy research and practice 20110101

• Combined modality approaches in the management of adult glioblastoma.

  Frontiers in oncology 20110101

• Investigational approaches for mesothelioma.

  Frontiers in oncology 20110101

• A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101210

• [Chemotherapy and targeted treatments in glioblastomas].

  Neuro-Chirurgie 20101201

• Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

  Leukemia & lymphoma 20101201

• Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.

  Anti-cancer agents in medicinal chemistry 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Characterisation and identification of the human N+-glucuronide metabolite of cediranib.

  Journal of pharmaceutical and biomedical analysis 20101102

• Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101101

• Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.

  European journal of medicinal chemistry 20101101

• Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.

  Cancer research 20101101

• Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.

  Oncotarget 20101101

• Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

  British journal of cancer 20101026

• In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.

  Drug metabolism and disposition: the biological fate of chemicals 20101001

• Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.

  Cancer chemotherapy and pharmacology 20100901

• Molecularly targeted therapy in hepatocellular carcinoma.

  Biochemical pharmacology 20100901

• Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.

  Expert review of anticancer therapy 20100901

• Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.

  British journal of cancer 20100810

• Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100801

• [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].

  Der Nervenarzt 20100801

• Stratifying osteosarcoma: minimizing and maximizing therapy.

  Current oncology reports 20100701

• Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100610

• Targeted therapies in renal cell cancer: recent developments in imaging.

  Targeted oncology 20100601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100601

• Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

  Journal of the National Cancer Institute 20100505

• Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

  Neuro-oncology 20100501

• Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.

  The oncologist 20100501

• Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

  Angiogenesis 20100301

• Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

  Clinical journal of the American Society of Nephrology : CJASN 20100301

• Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

  European journal of cancer (Oxford, England : 1990) 20100301

• Tyrosine kinase inhibitors to treat liver cancer.

  Expert opinion on emerging drugs 20100301

• Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

  Neuro-oncology 20100301

• Recent advances and future directions in the management of metastatic renal cell carcinoma.

  Anti-cancer agents in medicinal chemistry 20100301

• Treatment options for small cell lung cancer - do we have more choice?

  British journal of cancer 20100216

• An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

  Leukemia research 20100201

• CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.

  British journal of cancer 20100119

• Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

  British journal of cancer 20100105

• Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100101

• CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

  Cancer biology & therapy 20100101

• A current review of targeted therapeutics for ovarian cancer.

  Journal of oncology 20100101

• Antivascular therapy for epithelial ovarian cancer.

  Journal of oncology 20100101

• Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.

  PloS one 20100101

• Targeted therapies in epithelial ovarian cancer.

  Journal of oncology 20100101

• Targeted therapy in ovarian cancer.

  Journal of oncology 20100101

• Angiogenesis inhibition in prostate cancer: current uses and future promises.

  Journal of oncology 20100101

• Progress on antiangiogenic therapy for patients with malignant glioma.

  Journal of oncology 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

  Molecular cancer 20100101

• Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

  Journal of oncology 20100101

• Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

  Journal of oncology 20100101

• Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

  Molecular cancer 20100101

• Clinical trials with anti-angiogenic agents in hematological malignancies.

  Journal of angiogenesis research 20100101

• Angiogenesis inhibitors in the treatment of prostate cancer.

  Journal of hematology & oncology 20100101

• Targeting lymphatic vessel functions through tyrosine kinases.

  Journal of angiogenesis research 20100101

• Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.

  BMC cancer 20100101

• Treatment options for patients with triple-negative breast cancer.

  Journal of hematology & oncology 20100101

• Antiangiogenic therapy for breast cancer.

  Breast cancer research : BCR 20100101

• New developments in treatment of ovarian carcinoma: focus on trabectedin.

  Cancer management and research 20100101

• [New therapeutic options in therapy of glioblastoma multiforme].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.

  Therapeutic advances in medical oncology 20100101

• Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI.

  British journal of cancer 20091201

• Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.

  Anticancer research 20091201

• Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20091101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.

  Cancer chemotherapy and pharmacology 20091001

• Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.

  Expert opinion on investigational drugs 20091001

• Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

  Molecular cancer therapeutics 20090901

• Investigational agents in the management of non-small cell lung cancer.

  Current oncology reports 20090701

• A 'vascular normalization index' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

  Cancer research 20090701

• Treatment in advanced colorectal cancer: what, when and how?

  British journal of cancer 20090602

• VEGF inhibitors and prostate cancer therapy.

  Current molecular pharmacology 20090601

• Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

  Future oncology (London, England) 20090501

• [Second-line treatment using novel chemotherapeutic and biologic agents].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.

  Magnetic resonance imaging 20090401

• An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.

  Journal of neuro-oncology 20090401

• VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.

  Nature reviews. Clinical oncology 20090401

• A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.

  European journal of cancer (Oxford, England : 1990) 20090301

• The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.

  International journal of radiation oncology, biology, physics 20090301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090301

• Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

  Bioorganic & medicinal chemistry 20090115

• Antiangiogenic drugs in ovarian cancer.

  British journal of cancer 20090113

• Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

  Clinical colorectal cancer 20090101

• Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.

  Clinical & experimental metastasis 20090101

• PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.

  PloS one 20090101

• Current available therapies and future directions in the treatment of malignant gliomas.

  Biologics : targets & therapy 20090101

• VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.

  PloS one 20090101

• DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.

  Journal of angiogenesis research 20090101

• Acoustic radiation force and optical spectroscopy for assessing tumor vessel normalization during anti-angiogenic therapy.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20090101

• Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

  BMC cancer 20090101

• Targeted therapy in the treatment of malignant gliomas.

  OncoTargets and therapy 20090101

• New therapies for recurrent glioblastomas.

  F1000 medicine reports 20090101

• Current status of maintenance therapy for advanced ovarian cancer.

  International journal of women's health 20090101

• Novel anti-angiogenic therapies for malignant gliomas.

  The Lancet. Neurology 20081201

• Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

  Current cancer drug targets 20081201

• Novel drugs for renal cell carcinoma.

  Expert opinion on investigational drugs 20081001

• Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.

  The British journal of radiology 20081001

• Targeting angiogenesis in the treatment of lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• Speeding up the evaluation of new agents in cancer.

  Journal of the National Cancer Institute 20080903

• Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.

  Current opinion in supportive and palliative care 20080901

• Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.

  European journal of cancer (Oxford, England : 1990) 20080901

• Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.

  The oncologist 20080901

• [Tumor vasculature as a therapeutic target in non-small cell lung cancer].

  Magyar onkologia 20080901

• Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.

  Molecular cancer therapeutics 20080801

• The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

  Cancer research 20080615

• The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601

• Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080515

• Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080410

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080401

• Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

  Pediatric blood & cancer 20080301

• Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.

  Cancer 20080115

• Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).

  NMR in biomedicine 20080101

• The role of angiogenesis inhibitors in prostate cancer.

  Cancer journal (Sudbury, Mass.) 20080101

• Novel therapies in genitourinary cancer: an update.

  Journal of hematology & oncology 20080101

• Gateways to clinical trials. July-August 2008.

  Methods and findings in experimental and clinical pharmacology 20080101

• A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.

  Clinical medicine. Oncology 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071201

• Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).

  Investigational new drugs 20071001

• The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

  Molecular cancer therapeutics 20070801

• Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720

• Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.

  British journal of cancer 20070702

• The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

  European radiology 20070701

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070601

• AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.

  Reviews on recent clinical trials 20070501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.

  Molecular cancer therapeutics 20070201

• Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.

  Cancer cell 20070101

• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  Cancer cell 20070101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.

  Clinical & developmental immunology 20070101

• Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.

  Cancer research 20061201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061201

• Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

  Carcinogenesis 20061001

• Anti-angiogenic and anti-HER therapy.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060701

• A physiologic imaging pilot study of breast cancer treated with AZD2171.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060101

• Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.

  IDrugs : the investigational drugs journal 20051201

• A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer.

  Clinical breast cancer 20051201

• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  Cancer research 20050515

• Angiogenesis and lung cancer: prognostic and therapeutic implications.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510